Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Completed · Phase 2

Conditions studied: Pituitary Tumors

In brief

Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate receptor. The study is designed as an open-label, baseline-controlled study.

Key facts

Study ID

NCT01689727

Run by

Endocyte

People needed

40

Starts

2002-09-01

Last updated by the study team

2023-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must meet the following eligibility requirements to be enrolled in the study:
• Subject must be 18 years of age or older.
• Subject must have a pituitary tumor.
• Subject must have good kidney function.
• Subject must provide written informed consent prior to enrollment.

You may not qualify if…

• Subjects must be excluded if any of the following conditions are present:
• Subject is pregnant or breastfeeding.
• Subject is simultaneously participating in another investigational drug study.
• Subject has completed the follow-up phase of any previous study loess than 30 days prior to enrollment in this study.
• Subject is unable to tolerate conditions for radionuclide imaging.
• Subject has been administered another radiopharmaceutical that would interfere with the assessment of Technetium Tc 99m EC20.

Where it is running

• Emory Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.